Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...